Preservation media, durations and cell concentrations of short-term storage affect key features of human adipose-derived mesenchymal stem cells for therapeutic application

Fengli Zhang, Huaijuan Ren, Xiaohu Shao, Chao Zhuang, Yantian Chen Corresp., Nianmin Qi Corresp.

1 Cell Culture and Bioprocess Engineering Lab, School of Pharmacy, Shanghai Jiao Tong University, Shanghai, China
2 China Stem Cell Therapy Co., Limited, Shanghai, Shanghai, China

Corresponding Authors: Yantian Chen, Nianmin Qi
Email address: ytchen@sjtu.edu.cn, biotech@sjtu.edu.cn

Background. Adipose-derived mesenchymal stem cells (ADSCs) have shown great potential in the treatment of various diseases. However, the optimum short-term storage condition of ADSCs in 2~8°C is rarely reported. This study aimed at optimizing a short-term storage condition to ensure the viability and function of ADSCs before transplantation. Methods. Preservation media and durations of storage were evaluated by cell viability, apoptosis, adhesion ability and colony-forming unit (CFU) capacity of ADSCs. The abilities of cell proliferation and differentiation were used to optimize cell concentrations. Optimized preservation condition was evaluated by cell surface markers, cell cycle and immunosuppressive capacity. Results. 5% human serum albumin in multiple electrolytes (ME+HSA) was the optimized medium with high cell viability, low cluster rate, good adhesion ability and high CFU capacity of ADSCs. Duration of storage should be limited to 24h to ensure the quality of ADSCs before transplantation. 5×10^6 cells/ml was the most suitable cell concentration with low late stage apoptosis, rapid proliferation and good osteogenic and adipogenic differentiation ability. This selected condition did not change surface markers, cell cycle, indoleamine 2, 3-dioxygenase 1 (IDO1) gene expression and kynurenine (Kyn) concentration significantly. Discussion. In this study, ME+HSA was found to be the best medium, most likely due to the supplement of HSA which could protect cells, the physiological pH (7.4) of ME and sodium gluconate ingredient in ME which could provide energy for cells. Duration should be limited to 24h because of reduced nutrient supply and increased waste and lactic acid accumulation during prolonged storage. 5×10^6 cells/ml is the proper cell concentration keep the proliferation of cells and limit lactic acid accumulation. Surface markers, cell cycle and immunosuppressive capacity did not change significantly after storage using the optimized condition, which confirmed our results that this optimized short-term storage condition of MSCs has a great potential for the application of cell therapy.
Preservation media, durations and cell concentrations of short-term storage affect key features of human adipose-derived mesenchymal stem cells for therapeutic application

Fengli Zhang¹, Huaijuan Ren¹, Xiaohu Shao¹, Chao Zhuang¹, Yantian Chen¹, *, Nianmin Qi¹, ², *

¹ Cell Culture and Bioprocess Engineering Lab, School of Pharmacy, Shanghai Jiao Tong University, Shanghai, China

² China Stem Cell Therapy Co., Limited, Shanghai, China

Corresponding Authors:

Yantian Chen¹
800 Dongchuan Road, Minhang District, Shanghai, 200240, China
Email Address: ytchen@sjtu.edu.cn

Nianmin Qi¹, ²
800 Dongchuan Road, Minhang District, Shanghai, 200240, China
Email Address: biotech@sjtu.edu.cn
Abstract

Background. Adipose-derived mesenchymal stem cells (ADSCs) have shown great potential in the treatment of various diseases. However, the optimum short-term storage condition of ADSCs in 2~8°C is rarely reported. This study aimed at optimizing a short-term storage condition to ensure the viability and function of ADSCs before transplantation.

Methods. Preservation media and durations of storage were evaluated by cell viability, apoptosis, adhesion ability and colony-forming unit (CFU) capacity of ADSCs. The abilities of cell proliferation and differentiation were used to optimize cell concentrations. Optimized preservation condition was evaluated by cell surface markers, cell cycle and immunosuppressive capacity.

Results. 5% human serum albumin in multiple electrolytes (ME+HSA) was the optimized medium with high cell viability, low cluster rate, good adhesion ability and high CFU capacity of ADSCs. Duration of storage should be limited to 24h to ensure the quality of ADSCs before transplantation. 5×10^6 cells/ml was the most suitable cell concentration with low late stage apoptosis, rapid proliferation and good osteogenic and adipogenic differentiation ability. This selected condition did not change surface markers, cell cycle, indoleamine 2, 3-dioxygenase 1 (IDO1) gene expression and kynurenine (Kyn) concentration significantly.

Discussion. In this study, ME+HSA was found to be the best medium, most likely due to the
supplement of HSA which could protect cells, the physiological pH (7.4) of ME and sodium gluconate ingredient in ME which could provide energy for cells. Duration should be limited to 24h because of reduced nutrient supply and increased waste and lactic acid accumulation during prolonged storage. $5 \times 10^6$ cells/ml is the proper cell concentration keep the proliferation of cells and limit lactic acid accumulation. Surface markers, cell cycle and immunosuppressive capacity did not change significantly after storage using the optimized condition, which confirmed our results that this optimized short-term storage condition of MSCs has a great potential for the application of cell therapy.

Introduction

The use of mesenchymal stem cells (MSCs) is a potential regenerative therapeutic strategy because of their regenerative and immune-regulatory properties [1]. Currently MSCs are widely used in treating various diseases, including immune disorders, degenerative diseases, and tissue injuries [2,3]. Although MSCs can be derived from almost every tissue of the body [4,5,6], adipose-derived MSCs (ADSCs) are ideal cells for further use in regenerative medicine due to the high abundance of ADSCs in adipose tissue and the minimal morbidity associated with harvesting MSCs from adipose tissue [7,8].

Large-scale application of MSCs in regenerative medicine demands clinically acceptable “off-the-shelf” cell therapy products. Stem cells cryopreserved using dimethyl sulfoxide (DMSO) are commonly used in regenerative medicine, however, a great number of observed adverse reactions were tenuously or convincingly associated with the cryoprotectant DMSO. Cerebral
infarction and myocardial injury occurred in two patients after intravenous injection of autologous stem cells with DMSO [9]. Neurotoxicity was observed in a patient who suffered from a generalized tonic seizure upon infusion of DMSO-cryopreserved peripheral blood stem cells [10]. During the infusion of hematopoietic stem cells without washing the DMSO a patient developed bradycardia, abdominal pain and nausea, and 24h later he developed anasarca and hypertension [11]. Other side effects caused by DMSO include cardiac arrest [12], severe respiratory arrest [13], paradoxical embolism [14], transient consciousness loss [15] and so on.

There are several alternative cryoprotectants, such as ethylene glycol, methanol and polymer hydroxyethyl starch, but these would cause cell injury and researchers have to focus on how to minimize or eliminate their toxicity [16]. In addition, sometimes brief (i.e., 24-48h) storage of MSCs is needed, but cryopreservation of MSCs is not a practical way for brief storage of MSCs [17,18,19,20]. The short-term storage of fresh MSCs in 2−8 ℃ does not require cryoprotectants which have underlying safety issues. Also it does not require complicated liquid nitrogen device, which means it can be used to improve the transportability of MSCs products.

In order to maintain high quality of MSCs during the time between harvesting and administration, the surrounding environment needs to be strictly controlled and some key factors must be taken into account [21]. Several factors including preservation media, durations of storage and cell concentrations may affect the viability and function of MSCs when suspended in liquid storage medium [20,22,23]. Different kinds of preservation media including M199 [24], PBS [25], NS [2], PlasmalyteA [23], 1%HSA in DMEM20, 20% HSA and 5% glucose in
Ringer’s lactate [21] have been used in previous studies. However, M199 and PBS are not approved vehicles for safe injections thus they could not be used clinically. The viability of cells stored in 1%HSA in DMEM decreased rapidly [20]. There was no quality evaluation of the cells suspended in NS [2]. Transplantation of cells immediately after the harvest could receive best clinical outcomes because the quality of cells before administration affects therapeutic efficacy greatly. However, it takes hours or days to progress from harvest to transplantation inevitably [26]. Thus, it is of great importance to optimize an appropriate duration of storage with clinically acceptable cell viability and function. Although cell viability in 20% HSA and 5% glucose in Ringer’s lactate was high (>80%) till 48h, there was no research on the proliferation and immunosuppressive capacity of MSCs [21]. It has been reported that cell concentrations may affect biological properties of hematopoietic stem cells and cell viability of non-MSC cell lines [27,28]. Thus we also evaluated the effects of cell concentrations during short-term storage on the characteristics of MSCs.

Short-term storage condition with high viability and function of ADSCs has not been studied systematically so far. We aimed to optimize a short-term storage condition to ensure the viability and function of ADSCs for therapeutic application.

Materials & Methods

Study design

This study consisted of four consecutive parts in which preceding results were applied in the
subsequent steps. In part I, the impact of different media was measured and the most suitable
medium was subsequently used throughout the study. NS and PlasmalyteA are commonly used
vehicles, and the supplement of HSA could protect cells from environmental stress and prevent
adherence to the tubes or vials [29]. Dextrose provides a source of energy for cell metabolism
[30]. Previous study reported that the best preservation medium for short-term storage was 5%
dextrose [31]. Thus we decided to study 5% human serum albumin in 0.9% normal saline
(NS+HSA), 5% human serum albumin in multiple electrolytes (ME+HSA, as Baxter Healthcare
Co., Ltd stopped production of PlasmalyteA here in China, ME with totally the same formula as
PlasmalyteA was chosen to substitute PlasmalyteA.), dextrose and growth medium (GM) by
measuring cell viability and cluster rates, adhesion ability, apoptosis and CFU capacity. In part II,
two durations (24h and 48h) of storage were evaluated by parameters described above and
optimized duration was applied in the following study. In part III, cell concentrations were
investigated by adopting measurement of proliferation and differentiation. In part IV,
quantification of surface markers, cell cycle, IDO1 gene expression and Kyn concentration of
ADSCs suspended in optimized concentration were studied. Cells were stored in 2ml cryogenic
vials (Corning Incorporated, USA) and then placed in a cold chain shipping container designed
to ensure stable cooled products transport (2~8℃; more than 50h). A continuous temperature
monitoring device was embedded in the cold chain shipping container. ADSCs were suspended
after storage in 2~8℃ for the following research. Unstored cells were fresh cells that did not
undergo storage.
Preparation of storage media

5% (500ml: 25g) dextrose injection was purchased from Baxter Healthcare (Shanghai) Co., Ltd, China. NS+HSA was prepared by adding 5ml 20%HSA (Shanghai Institute of Biological Products Co., Ltd, China) into 15ml NS (Hunan kelun Pharmaceutical Co., Ltd, China). ME+HSA was prepared by adding 5ml 20%HSA into 15ml ME (Sichuan kelun Pharmaceutical Co., Ltd, China). GM was $\alpha$-modified minimal essential medium ($\alpha$-MEM, Gibco, USA) supplemented with 10% fetal bovine serum (FBS, Gemini, Australia).

Isolation and culture of ADSCs

This study was approved by the Ethics Committee of the Shanghai First People’s Hospital at Shanghai Jiao Tong University (number 2013KY080). The 33 years old woman volunteer signed the contract and permitted adipose tissue to be used for storage and scientific research. The first passage of ADSCs was separated and cultured in GMP condition in Shanghai Kun’ai Biological Technology Co., LTD. Cells were seeded in 6-well plates, cultured with $\alpha$-MEM supplemented with 10% FBS and 1% penicillin/streptomycin and maintained at 37°C in a humidified atmosphere at 5% CO$_2$. Medium was changed every three days. Cells were passaged at approximately 80% confluence and passages 3 to 5 were used for the experiments.

Cell viability and apoptosis

Cell viability and cluster rates were determined on an automatic cell counter (Countstar, Shanghai Ruiyu Biotech Co., Ltd, China) using trypan blue (Gibco, USA) staining method.
Unstained cells were counted as live cells.

Cell apoptosis was analyzed using a FITC-conjugated Annexin V/PI assay kit (SAB, USA) as our previous study has reported [32]. 0.5 million cells were rinsed twice with PBS. After centrifugation, 500 μl buffer was added to suspend cells. 5 μl Annexin V-FITC was added to the cell suspension and cells were incubated in the dark for 20 min at 4°C, followed by addition of 10 μl PI and incubation in the dark for 5 min at 4°C. Cell apoptosis was determined by flow cytometry (BD Bioscience, USA) and analyzed using FlowJo software (TreeStar, USA).

**Adhesion ability**

1 million cells were seeded in a 100-mm cell culture dish (Corning Incorporated, USA) and allowed to attach for 24 h at 37°C in a humidified atmosphere at 5% CO₂. Cells were then observed and evaluated under an inverted microscope IX51 (Olympus, Japan).

**Colony-forming unit (CFU) capacity**

250 cells suspended in 2 ml α-MEM supplemented with 10% FBS were seeded in a 60-mm dish (Corning Incorporated, USA) or per well of a six-well plate (Corning Incorporated, USA). After culture for 10 days at 37°C in a humidified atmosphere at 5% CO₂, cells were rinsed twice with PBS and fixed with methanol for 20 min at -20°C. Then methanol was removed and cells were rinsed twice with PBS. Cells were stained with 1 ml 0.2% crystal violet (Sinopharm Chemical Reagent Ltd., China) for 1 h at room temperature. The plates were rinsed twice with PBS. Stained colonies with >50 cells were scored as CFU and counted under an inverted microscope.
Proliferation of ADSCs was assessed by a nontoxic metabolic indicator Alamar Blue (Life technologies, USA) as our previous study has reported [33]. In brief, cells were seeded in a 24-well plate (Corning Incorporated, USA) at a concentration of $2 \times 10^4$ cells/well. After culture for 24h, culture medium was changed into fresh medium containing 10%(v/v) Alamar Blue indicator and then cells were incubated in the dark for 3h at 37°C. Absorbance of the extracted dye was measured by an enzyme immunoassay analyzer (Thermo, USA) at wavelengths of 570 and 590nm.

Population-doubling time (PDT) was calculated according to the following equation:

$$PDT = t \times \lg 2/(\lg N_t - \lg N_0)$$

In the equation, $t$ indicated duration of proliferation, $N_t$ and $N_0$ represented harvesting cell number and initial seeding cell number, respectively.

**Differentiation assay**

**Adipogenic differentiation**

Cells were seeded in a 12-well plate (Corning Incorporated, USA) at a concentration of $1 \times 10^4$ cells/well and cultured with α-MEM supplemented with 10% FBS until 80% confluency. Cells in differentiation group were incubated with adipogenic induction medium.
consisted of α-MEM supplemented with 10% FBS, 1 μ M dexamethasone (Sigma, USA), 0.5M isobutylmethylxanthine (Sigma, USA), 10 μ M insulin (Sigma, USA) and 200 μ M indomethacin (Sigma, USA). Cells in control group were cultured with α-MEM supplemented with 10% FBS. Medium was changed every 3 days. After incubation for 3 weeks, cells were stained by Oil Red O (Sigma, USA) and observed under an inverted microscope. Then adipogenic differentiation was quantified by an enzyme immunoassay analyzer at 510nm after the elution with isopropyl alcohol for 10 min at room temperature.

**Osteogenic differentiation**

Cells were seeded in a 12-well plate at a concentration of $5 \times 10^3$ cells/well and cultured with α-MEM supplemented with 10% FBS until 80% confluency. Cells in differentiation group were incubated with osteogenic induction medium consisted of α-MEM supplemented with 10% FBS, 0.1 μ M dexamethasone, 10mM β-glycerophosphate (Sinopharm Chemical Reagent Ltd., China) and 200 μ M ascorbic acid (Sigma, USA). Cells in control group were cultured with α-MEM supplemented with 10% FBS. Medium was changed every 3 days. After incubation for 3 weeks, cells were stained by Alizarin red (Chroma-Schmidt GmbH, Germany) and observed under an inverted microscope. Then osteogenic differentiation was quantified by an enzyme immunoassay analyzer at 570nm after the solubilization with 10% cetylpyridinium chloride (Sigma, USA) for 10 min at room temperature.

**Quantification of surface markers**
The surface markers of the cells were examined by flow cytometry. Briefly, $2.5 \times 10^5$ cells were rinsed twice with PBS, and then suspended in PBS supplemented with 2% FBS. Cells were stained in the dark for 30 min at 4°C with the antibodies (BD Biosciences, USA): R-phycoerythrin-(PE)-labeled HLA-DR, CD34, CD45, CD73, CD90 and CD105. The control for PE-coupled antibodies was isotypic mouse IgG1. The data were evaluated using CellQuest software (BD Biosciences, USA) and analyzed by FlowJo software.

**Cell cycle**

The proportion of cells in different phases of cell cycle was analyzed by cell cycle staining buffer (Multiscience, China). Cells were rinsed twice with PBS and then incubated with buffer at a concentration of $1 \times 10^6$ cells/ml for 30 min in the dark at room temperature. Cell cycle was determined by flow cytometry and analyzed using FlowJo software.

**Immunosuppressive capacity**

IDO1 is a rate-limiting enzyme in the kynurenine pathway which plays an important role in the induction of immune tolerance. To assess the immunosuppressive capacity of ADSCs, IDO1 gene expression and IDO1 activity assay were performed. Kyn concentration was evaluated as an index which could reflect IDO1 activity.

After storage, cells were seeded in a six-well plate at a concentration of $5 \times 10^5$ cells/well. After culture for 24 h at 37°C in a humidified atmosphere at 5% CO$_2$, culture medium was changed into fresh medium supplemented with 500 U/ml IFN-γ (PEPROTECH, USA) and then
induced for 24h. In control group, unstored cells were seeded in a six-well plate, and then treated
using the same method as stored cells. Cells were used for IDO1 gene expression assay and
supernatant was collected for Kyn concentration assay.

**IDO1 gene expression**

After incubation for 24h, total RNA was extracted from ADSCs using RNAiso Plus Kit
(Takara, Japan) following the manufacturer’s protocol. Total RNA concentrations were
quantified using NanoDrop1000 (Thermo, USA). 1 μg total RNA was reserved. Real-time
polymerase chain reaction (PCR) was achieved by SYBR green system (Takara, Japan).
Amplifications for cDNA samples were carried out at 95°C for 30s, followed by 40cycles at 95°C
for 5s and at 60°C for 30s. Primer sequences were listed in Table 1. The relative quantification of
target gene was calculated using the 2^(-△△t) method and normalized to the transcript levels of
glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Melting curve profiles were produced at
the end of each PCR to confirm the specific transcriptions of amplification [33].

**Kyn concentration**

1ml cell supernatant was mixed with 250 μl 30% trichloroacetic acid (Sinopharm Chemical
Reagent Ltd., China) and the mixture was vortexed and centrifuged at 12000 rpm for 20min at
4°C. After filtration with 0.22 μM membrane (Life Science, USA), supernatant was analyzed by
high performance liquid chromatography LC-20AT (HPLC, Shimadzu, Japan) equipped with a
Phenomenex Gemini C18 (250×4.6mm, 5 μm) column. Mobile phase A was 1 μmol/l
potassium dihydrogen phosphate (pH=4, Sinopharm Chemical Reagent Ltd., China) and mobile 
phase B was methanol (Merck, USA). The rate of mobile phase A and B was 3:1 and the flow 
rate was 1ml/min. Kyn concentration was detected by the UV-detector at a wavelength of 360nm 
at room temperature.

Statistical analysis

All data were shown as mean ± standard deviation, and difference and significance were 
verified by an one-way analysis of variance (ANOVA), followed by the least-square difference 
(LSD) for multiple comparisons test. A level of significance of P <0.05 was used to indicate 
statistical differences. The statistical analysis was performed using SPSS 19 (SPSS Inc., USA).

Results

Part I: Evaluation of preservation media

Harvested ADSCs were suspended in dextrose, ME+HSA, NS+HSA and GM at a 
concentration of 1 × 10^6 cells/ml. After storage for 24h at 2~8℃, cells were used for the 
following research. Unstored cells were used as control.

The viability of cells in ME+HSA (95.88±0.69%) and NS+HSA (91.96±1.53%) were 
significantly higher than in dextrose (67.81±6.37%) (Fig. 1A, P<0.05). Cell viability in dextrose 
dropped off dramatically after storage for 24h. The cluster rate of cells in GM (26.99±1.84%) 
was significantly higher than that of cells in ME+HSA (3.44±0.81%), NS+HSA (4.23±2.46%) 
and dextrose(3.82±0.04%) (Fig. 1A, P<0.05). As shown in Fig. 1A, cells in GM clustered
obviously. These results indicated that dextrose, with low cell viability, and GM, with extremely high cluster rate, were not suitable media for the storage of ADSCs.

In our subsequent observation, we found the viability of cells after storage measured by trypan blue staining was not precise and sensitive enough, so we performed Annexin V/PI binding assay (Fig. 1B). The proportions of normal cells in dextrose, ME+HSA, NS+HSA and GM all decreased but there were no significant differences among them. The proportions of early stage apoptotic cells and late stage apoptotic cells both increased in dextrose, ME+HSA, NS+HSA and GM, but there were no significant differences among them, respectively.

The adhesion ability of ADSCs after storage was observed under an inverted microscope (Fig. 1C). Attached cells in the four groups after storage all showed similar spindle-shaped morphologies to cells in the unstored group. However, a mass of detached cells were obviously observed in NS+HSA, which indicated that a lot of cells lost their adhesion ability after storage in NS+HSA.

An evaluation of CFU capacity was performed on ADSCs (Fig. 1D). All groups could form colonies with >50 cells after culture for 10 days. However, the CFU of cells in ME+HSA (13.33 ± 2.05) was significantly higher than that of cells in NS+HSA (2.40 ± 1.06). These results indicated that ME+HSA was a better preservation medium than NS+HSA.

Based on the study of different preservation media, ME+HSA was selected as a proper preservation medium for high cell viability, low cell cluster rate, good adhesion ability and high
Part II: Evaluation of durations of storage

ME+HSA was selected as the storage medium for further study. The storage of ADSCs in ME+HSA for durations of 24h and 48h at 4°C at a concentration of $1 \times 10^6$ cells/ml were studied. Unstored cells were used as control.

The cell viability after storage for 48h (95.34±4.72%) was very high and there was no significant difference compared to cells stored for 24h (98.11±1.33%), as data were shown in Fig. S1. The cluster rate was lower after storage for 48h (7.98±1.20%) than after storage for 24h (15.06±1.34%). It seemed that cells could be stored in ME+HSA with high viability.

Apoptosis was evaluated at 24h and 48h after storage (Fig. 2A). The proportion of late stage apoptotic cells increased notably over storage time from 24h (29.13±3.22%) to 48h (41.53±1.15%). However, no significant difference in early stage apoptotic cells was shown over storage time from 24h (19.8±4.16%) to 48h(21.3±0.36%). These results indicated that extending the duration of storage from 24h to 48h would accelerate the apoptosis especially from early to late stage apoptosis.

Although the spindle-shaped morphology of attached cells did not change over the storage time (Fig. 2B), there were significantly fewer attached cells following storage for 48h than for 24h. The number of cells lost their adhesion ability increased obviously from 24h to 48h.

After storage for 48h, cells could form colonies with >50 cells (Fig. 2C), however, the
In conclusion, cells could not be stored in ME+HSA for 48h due to high level of apoptosis, poor adhesion ability and low CFU capacity although viability of cells suspended in ME+HSA for 48h was very high. 24h was shown to be an appropriate duration of storage, with relatively low proportion of late stage apoptosis, high adhesion ability and CFU capacity.

Part III: Evaluation of cell concentrations

ADSCs suspended in ME+HSA were stored for 24h at 2~8°C at various concentrations: $1 \times 10^6$ cells/ml, $5 \times 10^6$ cells/ml and $10 \times 10^6$ cells/ml. Unstored cells were used as control.

Apoptosis of cells in different cell concentrations was shown in Fig. 3A. The proportion of normal cells decreased obviously as the cell concentration increased from $1 \times 10^6$ cells/ml (50.6±3.66%) to $10 \times 10^6$ cells/ml (37±0.75%). Cells at a concentration of $5 \times 10^6$ cells/ml (30.40±2.87%) showed obviously higher level of early stage apoptosis than cells at $1 \times 10^6$ cells/ml (19.80±4.16%) and $10 \times 10^6$ cells/ml (23.33±3.66%) (P<0.05). Cells at concentrations of $1 \times 10^6$ cells/ml (29.13±3.22%) and $5 \times 10^6$ cells/ml (26.37±7.43%) showed lower level of late stage apoptosis than cells at $10 \times 10^6$ cells/ml (40.60±3.78%). These results indicated that cells stored at the concentration of $10 \times 10^6$ cells/ml would cause the highest level of late stage apoptosis.

Attached cells of all three groups could form spindle-shaped morphology (Fig. 3B), and it
seemed that there were no significant differences in adhesion ability among cells at three cell concentrations.

Cells could form colonies with > 50 cells at all three concentrations (Fig. 3C). There were no obvious differences in CFU numbers among cells suspended at $1 \times 10^6$cells/ml ($17.07 \pm 4.01$), $5 \times 10^6$cells/ml ($13.00 \pm 1.40$) and $10 \times 10^6$cells/ml ($15.47 \pm 1.29$). These results indicated that cell concentrations during the storage period did not impact on the CFU capacity.

Proliferation ability was shown in Fig. 4. The fluorescence value reached the peak at the 7th day in unstored cells and the PDT was $57.57 \pm 4.77$ h. The fluorescence values increased slowly until the 4th day in group $5 \times 10^6$cells/ml and group $10 \times 10^6$cells/ml, and then increased rapidly until reaching the peak on the 9th day with the PDT of $79.05 \pm 6.74$ h and $81.07 \pm 7.84$ h, respectively. There was no significant difference between group $5 \times 10^6$cells/ml and group $10 \times 10^6$cells/ml, in terms of either fluorescence values or PDT. As the fluorescence value in group $1 \times 10^6$cells/ml increased slowly with the time, it did not reach its peak before we stopped our measurement on the 10th day. These results indicated that cells in group $1 \times 10^6$cells/ml had low proliferation potential.

All of these three groups at different concentrations showed osteogenic differentiation (Fig. 5A) and adipogenic differentiation abilities (Fig. 5B). Osteogenic differentiation in group $5 \times 10^6$cells/ml ($0.09 \pm 0.01$) was slightly higher than in group $1 \times 10^6$cells/ml ($0.07 \pm 0.01$) or group $10 \times 10^6$cells/ml ($0.07 \pm 0.01$). Adipogenic differentiation ability in group $5 \times 10^6$cells/ml ($0.34 \pm 0.03$) was obviously higher than in group $1 \times 10^6$cells/ml ($0.18 \pm 0.02$) and group
10×10^6 cells/ml (0.16±0.01) (P<0.05). These results suggested that group 5×10^6 cells/ml had the best differentiation potential.

Level of apoptosis increased when the cell concentration increased from 1×10^6 cells/ml to 10×10^6 cells/ml. It seemed there were no obvious differences among the three groups in terms of adhesion ability or CFU capacity. Thus, we adopted the assays of proliferation and differentiation as two further evaluation parameters. Proliferation assay of group 1×10^6 cells/ml showed that low concentration would slower the growth of ADSCs and cells in group 5×10^6 cells/ml showed best osteogenic and adipogenic differentiation potential. These results suggested that 5×10^6 cells/ml was a suitable cell concentration for short-term storage.

**Part IV: Evaluation of optimized condition**

After the selection of preservative media, durations of storage and cell concentrations, we decided to store ADSCs in ME+HSA for 24h at a concentration of 5×10^6 cells/ml in 2~8℃. In order to give a comprehensive evaluation of our optimized condition, we studied the surface markers, cell cycle and immunosuppressive capacity of ADSCs after storage. Unstored cells were used as control.

After storage, HLA-DR, CD34 and CD45 were all negatively expressed (<2%), while CD73, CD90 and CD105 were all positively expressed (>95%, Fig. 6A). These results indicated that the storage of this optimized condition did not affect the expression of surface markers.

Flow cytometric analysis of cell cycle distribution was shown in Fig. 6B. After the storage,
there were no significant differences in G0/G1, S and G2/M compared with unstored cells, respectively. These results indicated that this optimized condition did not change the cell cycle distribution.

There was no significant fold difference in IDO1 gene expression between stored cells (3393.54 ± 653.65) and unstored cells (3654.41 ± 136.30, Fig. 6C). Also, there were no obvious differences in Kyn concentration between unstored cells (25.24 ± 1.75) and stored cells (27.45 ± 2.31, Fig. 6D). These results indicated that this optimized condition did not change gene expression and activity of IDO1.

Discussion

Adipose tissue was considered to be merely a passive energy store in previous years, before ADSCs could be isolated from adipose tissue as a new source of stem cells in 2001 [34]. ADSCs are multipotent cells with the ability to differentiate into both mesodermal and non-mesodermal lineages, similar to bone marrow-derived stem cells (BM-MSCs). In addition, ADSCs have a great number of advantages over BM-MSCs. ADSCs could be collected in large quantity with minimal morbidity [35], and derivation of ADSCs is easier (less invasive) and much more efficient than that of BM-MSCs. Thus ADSCs are attractive stem cells for regenerative application.

In order to manufacture a clinical-scale large number of ADSCs for cell therapy in regenerative medicine and tissue engineering, strictly quality control is required which means
that a cGMP-compliant clean room is needed. It seems impossible to build an expensive cGMP-compliant clean room in the hospital set-up, thus cell products should be produced in a central laboratory for up-scaling cells and then transported to the bedside of the patient [31]. Although cryopreservation is an alternative for long-term storage of ADSCs, its requirement for toxic cryoprotectants (i.e. DMSO) and low recovery rate of cells demonstrated that it is not the best or the safest condition for the short-term storage of cell products [23,36]. There is no standard protocol for short-term storage of fresh cells before transplantation as well as no relatively comprehensive evaluation of cell quality after storage. Previous study reported that MSCs stored in saline or dextrose for more than 2h lost cell viability significantly. MSCs lost CFU capacity and differentiation ability rapidly as storage time increased. Thus duration of storage was limited to 2h to ensure the quality of MSCs [26]. Although Plasmalyte A, 1% HSA and 5% HSA were FDA approved injections and typically used as preservation media prior to MSCs transplantation, none of these single components supported the survival of MSCs [23]. No duration information was given in a clinical trial of MSCs stored in saline for the treatment of ischemic stroke [37]. Cell concentration was considered to have an impact on cell quality, but researchers only measured MSCs counts among cells at the concentrations over a range of $0.5 \times 10^6$ to $20 \times 10^6$ cells/ml as the evaluation of cell quality [20]. Other researchers reported few or no details about preservation conditions or the effect of short-term storage on MSCs [38,39,40,41]. The primary objective of this study was to optimize preservation media, durations of storage and cell concentrations of ADSCs to provide a feasible short-term storage condition for cell therapy.
Results showed that cells formed clotted cell pellet after storage in GM for 24h, which confirmed the natural preference of MSCs to form aggregates [42]. Thus it would be unsafe clinically to inject cells suspended in GM. In addition, FBS in GM remains associated with safety issues including transmission of viral disease, anaphylactic reactions and production of anti-FBS antibodies [29,43,44]. Therefore, GM is not a suitable preservation medium for the short-term storage of ADSCs. When stored in dextrose, dark blue stained cells could be seen obviously. The viability of ADSCs suspended in dextrose decreased to 67.81 ± 6.37%, which was lower than the minimum viability (70%) acceptable by FDA for cell therapy. The deterioration of ADSCs survival in dextrose may be caused by the low-pH level (3.2-5.5).

Additionally, high concentration of 5% dextrose (50g/L) affects regenerative potential of MSCs and induces replicative senescence [23]. The adhesion ability and CFU capacity of ADSCs in NS+HSA were obviously lower than in ME+HSA respectively, despite the fact that the viability and apoptosis of cells in NS+HSA had no significant differences compared to cells in ME+HSA respectively. Thus a comprehensive evaluation system was needed to test the quality of cells before administration as rapid detection of viability and apoptosis would not always be reliable parameters. The mechanism of different effects on cell quality between ME+HSA and NS+HSA was not clear. We supposed that pH of two media may cause the difference as ME has physiological pH (7.4) while NS has lower pH (4.5-7.0). Also the sodium gluconate ingredient in ME could provide energy for cell survival.

Another point to discuss is the proper duration of short-term storage. We thought 24h was
enough for the transport of cell products to another city thousands of kilometers away and for the
preparation of both patients and doctors. We also wanted to investigate the longest duration with
>70% cell viability. Results showed that the viability of cells in 48h was high (>90%), however,
the late stage apoptosis rate in 48h was also high (41.53 ± 1.15%). The adhesion ability was poor
and CFU capacity was low (8.67 ± 1.67). High level of late stage apoptosis, poor adhesion ability
and low CFU capacity showed that cells could not adequately be stored for 48h. These results
may be a consequence of reduced nutrient supply and increase in waste and lactic acid
accumulation during prolonged storage [45]. The late stage apoptosis of cells (29.13 ± 3.22%) stored for 24h was acceptable, and the CFU number (17.07 ± 4.01) of cells stored for 24h was relatively high. All these results suggested that cells suspended in ME+HSA could be stored for 24h before administration.

Cell concentration during the storage is also an important factor which may affect cell quality. Compared to intravenous injection, subcutaneous injection and intramuscular injection require higher concentrated cell products with smaller volumes. As previous study has reported [28], MSCs suspension injected into small tendinous lesions would leak outside the defect and into the peritendinous tissue even the volume of cell suspension was only 1ml. Thus cell products of high cell concentration are needed. We compared three cell concentrations $1 \times 10^6$ cells/ml, $5 \times 10^6$ cells/ml and $10 \times 10^6$ cells/ml. Late stage apoptotic rate increased as the cell concentration increased. We didn’t observed significantly differences among these three groups in terms of adhesion ability and CFU capacity. Thus, we adopted the evaluation of
proliferation and differentiation. The proliferation of cells stored at a concentration of

$5 \times 10^6$ cells/ml was very close to that of cells stored at $10 \times 10^6$ cells/ml and significantly faster than that of cells stored at $1 \times 10^6$ cells/ml. Cells stored at $5 \times 10^6$ cells/ml showed the best osteogenic and adipogenic differentiation potential. The high level of late stage apoptosis of cells stored at $10 \times 10^6$ cells/ml may be explained that the highest cell concentration may be associated with the fastest lactic acid accumulation [46]. To some extent, decreasing cell concentration to limit lactic acid accumulation could enhance cell viability and improve cell function [22]. Long-term proliferation kinetics results indicated that the proliferation potential of cells stored at $1 \times 10^6$ cells/ml was impaired. Although increasing cell concentration could improve the proliferation potential, it seemed $5 \times 10^6$ cells/ml was high enough as the curve of it was very close to that of $10 \times 10^6$ cells/ml. Osteogenic and adipogenic differentiation results also suggested that $5 \times 10^6$ cells/ml was a suitable cell concentration. As previous study have reported the same cell concentration of $5 \times 10^6$ cells/ml as our result for cell therapy [47,48], we thought cells suspended at $5 \times 10^6$ cells/ml could have the highest quality among these three concentrations.

After the evaluation of preservation media, durations of storage and cell concentrations, we thought cells suspended in ME+HSA at a concentration of $5 \times 10^6$ cells/ml could be stored for 24h at 2~8°C before administration. Then we evaluated this condition by studying surface markers, cell cycle and immunosuppressive capacity of ADSCs after storage. Results showed that surface markers, cell cycle and immunosuppressive capacity did not change after the storage, which confirmed our result that this optimized condition has a great potential for the short-term
storage of MSCs for cell therapy.

**Conclusions**

This is the first study to optimize a short-term storage condition of ADSCs comprehensively. Key factors during short-term storage including preservation media, durations and cell concentrations are studied. Comprehensive evaluation is needed to reflect real cell status before transplantation. Our results show that ADSCs suspended in ME+HSA, at a concentration of 5 × 10⁶ cells/ml could be stored for 24h at 2~8°C, which provides a reliable short-term storage condition for cell therapy. Future studies are still needed to improve cell viability, extend duration of storage, and verify the therapeutic effect of ADSCs after short-term storage *in vivo.*
References

[1] M Kaplan J, E Youd M, A Lodie T. 2011. Immunomodulatory activity of mesenchymal stem cells. Current stem cell research & therapy 6(4): 297-316. DOI: 10.2174/157488811797904353.

[2] Venkataramana N K, Kumar S K V, Balaraju S, Radhakrishnan R C, Bansal A, Dixit A, Rao D K, Das M, Jan M, Gupta P K, Totey S M. 2010. Open-labeled study of unilateral autologous bone-marrow-derived mesenchymal stem cell transplantation in Parkinson's disease. Translational Research 155(2): 62-70.DOI: 10.1016/j.trsl.2009.07.006.

[3] Wei X, Yang X, Han Z, Qu F, Shao L, Shi Y. 2013. Mesenchymal stem cells: a new trend for cell therapy. Acta Pharmacologica Sinica 34(6): 747-754. DOI: 10.1038/aps.2013.50.

[4] da Silva Meirelles L, Chagastelles P C, Nardi N B. 2006. Mesenchymal stem cells reside in virtually all post-natal organs and tissues. Journal of cell science 119(11): 2204-2213. DOI: 10.1242/jcs.02932.

[5] Kern S, Eichler H, Stoewe J, Klüter H, Bieback K. 2006. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem cells 24(5): 1294-1301. DOI: 10.1634/stemcells.2005-0342.

[6] Mosna F, Sensebé L, Krampera M. 2010. Human bone marrow and adipose tissue mesenchymal stem cells: a user's guide. Stem cells and development 19(10): 1449-1470. DOI:10.1089/scd.2010.0140.

[7] Bajek A, Gurtowska N, Olkowska J, Kazmierski L, Maj M, Drewa T. 2016. Adipose-Derived stem cells as a Tool in Cell-Based therapies. Archivum immunologiae et therapiae experimentalis 64(6): 443-454. DOI:10.1007/s00005-016-0394-x.

[8] Gomez-Mauricio R G, Acarregui A, Sánchez-Margallo F M, Crisóstomo V, Gallo I, Hernández R M, Pedraz J L. 2013. A preliminary approach to the repair of myocardial infarction using adipose tissue-derived stem cells encapsulated in magnetic resonance-labelled alginate microspheres in a porcine model. European Journal of Pharmaceutics and Biopharmaceutics 84(1): 29-39. DOI: 10.1016/j.ejpb.2012.11.028.

[9] Chen-Plotkin A S, Vossel K A, Samuels M A, Chen M H. 2007. Encephalopathy, stroke, and myocardial infarction with DMSO use in stem cell transplantation. Neurology 68(11): 859-861. DOI: 10.1212/01.wnl.0000256716.04218.5b.

[10] Mueller L P, Theurich S, Christopeit M, Grothe W, Muetherig A, Weber T, Guenther S, Behre G. 2007. Neurotoxicity upon infusion of dimethylsulfoxide - cryopreserved peripheral blood stem cells in patients with and without pre-existing cerebral disease. European journal of haematology 78(6): 527-531. DOI: 10.1111/j.1600-0609.2007.00851.x.

[11] Ruiz-Delgado G J, Mancías-Guerra C, Tamez-Gómez E L, Rodríguez-Romo L N, López-Otero A, Hernández-Arizpe A, Gómez-Almaguer D, Ruiz-Argüelles G J. 2009. Dimethyl sulfoxide-induced toxicity in cord blood stem cell transplantation: report of three cases and review of the literature. Acta haematologica 122(1): 1-5. DOI: 10.1159/000227267.
[12] Rapoport A P, Rowe J M, Packman C H, Ginsberg S J. 1991. Cardiac arrest after autologous marrow infusion. *Bone marrow transplantation* 7(5): 401-403.

[13] Benekli M, Anderson B, Wentling D, Bernstein S, Czuczman M, McCarthy P. 2000. Severe respiratory depression after dimethylsulphoxide-containing autologous stem cell infusion in a patient with AL amyloidosis. *Bone marrow transplantation* 25(12). DOI: 10.1038/sj.bmt.1702452.

[14] Darabi K, Brown J R, Kao G S. 2005. Paradoxical embolism after peripheral blood stem cell infusion. *Bone marrow transplantation* 36(6): 561-562. DOI: 10.1038/sj.bmt.1705088.

[15] Schlegel P G, Wölf M, Schick J, Winkler B, Eyrich M. 2009. Transient loss of consciousness in pediatric recipients of dimethylsulfoxide (DMSO)-cryopre-served peripheral blood stem cells independent of morphine co-medication. *Haematologica* 94(10): 1473-1475. DOI: 10.3324/haematol.2009.009860.

[16] Marquez-Curtis L A, Janowska-Wieczorek A, McGann L E, Elliott J A. 2015. Mesenchymal stromal cells derived from various tissues: biological, clinical and cryopreservation aspects. *Cryobiology* 71(2): 181-197. DOI: 10.1016/j.cryobiol.2015.07.003.

[17] Haack-Sorensen M, Bindslev L, Mortensen S, Friis T, Kastrup J. 2007. The influence of freezing and storage on the characteristics and functions of human mesenchymal stromal cells isolated for clinical use. *Cytotherapy* 9(4): 328-337. DOI: 10.1080/14653240701322235.

[18] Lazarus H M, Koc O N, Devine S M, Curtin P, Maziarz R T, Holland H K, Shpall E J, McCarthy P, Atkinson K, Cooper B W, Gerson L S, Loberiza F Jr, Moseley A B, Bacigalupo A. 2005. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. *Biology of blood and marrow transplantation* 11(5): 389-398. DOI: 10.1016/j.bbmt.2005.02.001.

[19] Kim D W, Chung Y J, Kim T G, Kim Y L, Oh I H. 2004. Cotransplantation of third-party mesenchymal stromal cells can alleviate single-donor predominance and increase engraftment from double cord transplantation. *Blood* 103(5): 1941-1948. DOI: 10.1182/blood-2003-05-1601.

[20] Lane T A, Garls D, Mackintosh E, Kohli S, Cramer S C. 2009. Liquid storage of marrow stromal cells. *Transfusion* 49(7): 1471-1481. DOI: 10.1111/j.1537-2995.2009.02138.x.

[21] Gálvez-Martín P, Hmadcha A, Soria B, Calpena-Campmany AC, Clares-Navares B. 2014. Study of the stability of packaging and storage conditions of human mesenchymal stem cell for intra-arterial clinical application in patient with critical limb ischemia. European Journal of Pharmaceutics and Biopharmaceutics 86(3): 459-468. DOI: 10.1016/j.ejpb.2013.11.002.

[22] Kao G S, Kim H T, Daley H, Ritz J, Burger S R, Kelley L, Vierra-Green C, Flesch S, Spellman S, Miller J, Confer D. 2011. Validation of short-term handling and storage conditions for marrow and peripheral blood stem cell products. *Transfusion* 51(1): 137-147. DOI: 10.1111/j.1537-2995.2010.02758.x.

[23] Chen Y, Yu B, Xue G, Zhao J, Li RK, Liu Z, Niu B. 2013. Effects of storage solutions on the viability of human umbilical cord mesenchymal stem cells for transplantation. *Cell transplantation* 22(6): 1075-1086. DOI: 10.3727/096368912X657602.

[24] Mohamadnejad M, Alimoghaddam K, Mohyeddin-Bonab M, Bagheri M, Bashtari M, Ghanaati
H Baharvand H, Ghavamzadeh A, Malekzadeh R. 2007. Phase 1 trial of autologous bone marrow mesenchymal stem cell transplantation in patients with decompensated liver cirrhosis. Arch Iran Med 10(4): 459-466. DOI: 07104/AIM.008.

[25] Wang D, Zhang F, Shen W, Chen M, Yang B, Zhang Y, Cao K. 2011. Mesenchymal stem cell injection ameliorates the inducibility of ventricular arrhythmias after myocardial infarction in rats. International journal of cardiology 152(3): 314-320. DOI: 10.1016/j.ijcard.2010.07.025.

[26] Sohn H S, Heo J S, Kim H S, Choi Y, Kim H O. 2013. Duration of in vitro storage affects the key stem cell features of human bone marrow-derived mesenchymal stromal cells for clinical transplantation. Cytotherapy 15(4): 460-466. DOI: 10.1016/j.jcyt.2012.10.015.

[27] De Loecker W, Koptelov V A, Grischenko V I, De Loecker P. 1998. Effects of cell concentration on viability and metabolic activity during cryopreservation. Cryobiology 37(2): 103-109. DOI: 10.1006/cryo.1998.2106.

[28] Espina M, Jülke H, Brehm W, Ribitsch I, Winter K, Delling U. 2016. Evaluation of transport conditions for autologous bone marrow-derived mesenchymal stromal cells for therapeutic application in horses. PeerJ 4: e1773. DOI: 10.7717/peerj.1773.

[29] Ikebe C, Suzuki K. 2014. Mesenchymal stem cells for regenerative therapy: optimization of cell preparation protocols. BioMed research international 2014. DOI: 10.1155/2014/951512.

[30] Anderson R V, Siegman M G, Balaban R S, Ceckler T L, Swain J A. 1992. Hyperglycemia increases cerebral intracellular acidosis during circulatory arrest. The Annals of thoracic surgery 54(6): 1126-1130.

[31] Pal R, Hanwate M, Totey S M. 2008. Effect of holding time, temperature and different parenteral solutions on viability and functionality of adult bone marrow - derived mesenchymal stem cells before transplantation. Journal of tissue engineering and regenerative medicine 2(7): 436-444. DOI: 10.1002term.109.

[32] Ren H, Sang Y, Zhang F, Liu Z, Qi N, Chen Y. 2016. Comparative analysis of human mesenchymal stem cells from umbilical cord, dental pulp, and menstrual blood as sources for cell therapy. Stem cells international 2016. DOI: 10.1155/2016/351674.

[33] Chen Y, Zhang F, Fu Q, Liu Y, Wang Z, Qi N. 2016. In vitro proliferation and osteogenic differentiation of human dental pulp stem cells in injectable thermo-sensitive chitosan/beta-glycerophosphate/hydroxyapatite hydrogel. Journal of biomaterials applications 31:317-27. DOI: 10.1177/0885328216661566.

[34] Zuk P A, Zhu M, Mizuno H, Huang J, Futrell J W, Katz A J, Benhaim P, Lorenz H P, Hedrick M H. 2001. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue engineering 7(2): 211-228. DOI: 10.1089/107632701300062859.

[35] Uzbas F, May I D, Parisi A M, Thompson S K, Kaya A, Perkins A D, Memili E. 2015. Molecular physiognomies and applications of adipose-derived stem cells. Stem Cell Reviews and Reports 11(2): 298-308. DOI: 10.1007/s12015-014-9578-0.

[36] Grein T A, Freimark D, Weber C, Hudel K, Wallrapp C, Czermak P. 2010. Alternatives to
dimethylsulfoxide for serum-free cryopreservation of human mesenchymal stem cells. *The International journal of artificial organs* 33(6): 370-380.

[37] Bang O Y, Lee J S, Lee P H, Lee G. 2005. Autologous mesenchymal stem cell transplantation in stroke patients. *Annals of neurology* 57(6): 874-882. DOI: 10.1002/ana.20501.

[38] Li Y, Chen J, Chen X G, Wang L, Gautam S C, Xu Y X, Katakowski M, Zhang L J, Lu M, Janakiraman N, Chopp M. 2002. Human marrow stromal cell therapy for stroke in rat neurotrophins and functional recovery. *Neurology* 59(4): 514-523.

[39] Li Y, Chen J, Zhang C L, Wang L, Lu D, Katakowski M, Gao Q, Shen LH, Zhang J, Lu M, Chopp M. 2005. Gliosis and brain remodeling after treatment of stroke in rats with marrow stromal cells. *Glia* 49(3): 407-417. DOI: 10.1002/glia.20126.

[40] Kim D H, Yoo K H, Yim Y S, Choi J, Lee S H, Jung H L, Sung K W, Yang S E, Oh W I, Yang Y S, Kim S H, Choi S Y, Koo H H. 2006. Cotransplanted bone marrow derived mesenchymal stem cells (MSC) enhanced engraftment of hematopoietic stem cells in a MSC-dose dependent manner in NOD/SCID mice. *Journal of Korean medical science* 21(6): 1000-1004. DOI: 10.3346/jkms.2006.21.6.1000.

[41] Shen L H, Li Y, Chen J, Zhang J, Vanguri P, Borneman J, Chopp M. 2006. Intracarotid transplantation of bone marrow stromal cells increases axon-myelin remodeling after stroke. *Neuroscience* 137(2): 393-399. DOI: 10.1016/j.neuroscience.2005.08.092.

[42] Potapova I A, Brink P R, Cohen I S, Doronin SV. 2008. Culturing of human mesenchymal stem cells as three-dimensional aggregates induces functional expression of CXCR4 that regulates adhesion to endothelial cells. *Journal of Biological Chemistry* 283(19): 13100-13107. DOI: 10.1074/jbc.M800184200.

[43] Mackensen A, Dräger R, Schlesier M, Mertelsmann R, Lindemann A. 2000. Presence of IgE antibodies to bovine serum albumin in a patient developing anaphylaxis after vaccination with human peptide-pulsed dendritic cells. *Cancer Immunology, Immunotherapy* 49(3): 152-156.

[44] Sundin M, Ringdén O, Sundberg B, Nava S, Götherström C, Le Blanc K. 2007. No alloantibodies against mesenchymal stromal cells, but presence of anti-fetal calf serum antibodies, after transplantation in allogeneic hematopoietic stem cell recipients. *Haematologica* 92(9): 1208-1215.

[45] Robinson N J, Picken A, Coopman K. 2014. Low temperature cell pausing: an alternative short-term preservation method for use in cell therapies including stem cell applications. *Biotechnology letters* 36(2): 201-209. DOI: 10.1007/s10529-013-1349-5.

[46] Kilkson H, Holme S, Murphy S. 1984. Platelet metabolism during storage of platelet concentrates at 22 degrees C. *Blood* 64(2): 406-414.

[47] Garvican E R, Cree S, Bull L, Smith R K, Dudhia J. 2014. Viability of equine mesenchymal stem cells during transport and implantation. *Stem cell research & therapy* 5(4): 1. DOI: 10.1186/scrt483.

[48] Godwin E E, Young N J, Dudhia J, Beamish IC, Smith RK. 2012. Implantation of bone marrow - derived mesenchymal stem cells demonstrates improved outcome in horses with overstrain injury of the superficial digital flexor tendon. *Equine Veterinary Journal* 44(1): 25-32. DOI: 10.1111/j.2042-3306.2011.00363.x.
**Table 1** (on next page)

Real-time PCR primer sequences.
| Gene | Forward primer     | Reverse primer     |
|------|-------------------|-------------------|
| IDO1 | CTGGGCATCCAGCAGACT | TGAGCTGGCTGCATATCTTCT |
| GAPDH| AACAGCGACACCCACTCCT | CATACCAGGAAATGAGCTTGACAA |
Figure 1

Optimization of preservation media.

(A) Photos of cells on counting chamber and analysis of viability and cluster rate. *White arrow* indicated cell cluster. (B) Apoptosis analysis by flow cytometry. (C) Morphology of cells replated on 100-mm dish after storage. (D) Photos and analysis of CFU. Results were presented as the means ± standard deviation for n=3, *P<0.05.
Figure 2

Optimization of durations.

(A) Apoptosis analysis of ADSCs in different durations by flow cytometry. (B) Morphology of cells re-plated on 100-mm dish. (C) CFU of cells in different durations. Results were presented as the means ± standard deviation for n=3, *P<0.05.
Figure 3

Optimization of cell concentrations.

(A) Apoptosis analysis of ADSCs by flow cytometry. (B) Morphology of cells re-plated on 100-mm dish. (C) CFU of cells at different concentrations. Results were presented as the means ± standard deviation for n=3, *P<0.05.
Figure 4

Proliferation of ADSCs at different cell concentrations.

Results were presented as the means ± standard deviation for n=3, *P<0.05.
Figure 5

Multidifferentiation of ADSCs at different cell concentrations (A) Osteogenic differentiation. (B) Adipogenic differentiation.

Results were presented as the means ± standard deviation for n=3, *P<0.05.
Figure 6

Evaluation of optimized solution.

(A) HLA-DR, CD34, CD45, CD73, CD90, CD105 expression. (B) Cell cycle distribution. (C) IDO1 gene expression by RT-PCR. (D) Kyn concentration by HPLC. Results were presented as the means ± standard deviation for n=3.